Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Institutional investors boost stakes in Solventum, amid mixed analyst ratings and a consensus "Hold."
MetLife Investment Management and several other institutional investors increased their stakes in Solventum Co., a healthcare company with four business segments.
Mizuho initiated coverage with a neutral rating and a $70 price target, while other firms have varied ratings and targets, leading to a consensus "Hold" with a $68.29 target price.
Solventum's stock ranges between a 1-year low of $47.16 and a high of $96.05.
5 Articles
Los inversores institucionales impulsan las acciones en Solventum, en medio de calificaciones mixtas de analistas y un consenso de "Aguanta".